Litcius/Paper detail

Risk Factors of Daptomycin-Induced Eosinophilic Pneumonia in a Population with Osteoarticular Infection

Laura Soldevila‐Boixader, Bernat Villanueva, Marta Ulldemolins, Eva Benavent, Ariadna Padullés, Alba Ribera, I. Borras, Javier Ariza, Óscar Murillo

2021Antibiotics29 citationsDOIOpen Access PDF

Abstract

BACKGROUND: Daptomycin-induced eosinophilic pneumonia (DEP) is a rare but severe adverse effect and the risk factors are unknown. The aim of this study was to determine risk factors for DEP. METHODS: A retrospective cohort study was performed at the Bone and Joint Infection Unit of the Hospital Universitari Bellvitge (January 2014-December 2018). To identify risk factors for DEP, cases were divided into two groups: those who developed DEP and those without DEP. RESULTS: = 229) we identified 11 DEP cases (4.8%) and this percentage almost doubled in the subgroup of patients ≥70 years (8.1%). The risk factors for DEP were age ≥70 years (HR 10.19, 95%CI 1.28-80.93), therapy >14 days (7.71, 1.98-30.09) and total cumulative dose of daptomycin ≥10 g (5.30, 1.14-24.66). CONCLUSIONS: Clinicians should monitor cumulative daptomycin dosage to minimize DEP risk, and be cautious particularly in older patients when the total dose of daptomycin exceeds 10 g.

Topics & Concepts

DaptomycinEosinophilic pneumoniaMedicinePneumoniaEosinophilicPopulationIntensive care medicineInternal medicineRespiratory diseasePathologyEnvironmental healthLungStaphylococcus aureusBiologyVancomycinGeneticsBacteriaOrthopedic Infections and TreatmentsInterstitial Lung Diseases and Idiopathic Pulmonary FibrosisPneumocystis jirovecii pneumonia detection and treatment
Risk Factors of Daptomycin-Induced Eosinophilic Pneumonia in a Population with Osteoarticular Infection | Litcius